Autopsy report · NCT01497626

Lapatinib and Bortezomib in Patients With Advanced Malignancies

“Drug support withdrawn”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 4 years 3 months before it stopped.
• 15 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Georgetown University

Sponsor type

University, hospital or other

Conditions

Advanced Solid Tumors

Interventions

Lapatinib and bortezomib

Participants

15

Sites

1

Countries

United States

Trials that died the same way

• The Sub-Sero Study
  “Drug supply withdrawn (dec 2019)” (78% match in meaning)
• Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
  “Withdrawal of drug supply/funding” (76% match in meaning)
• A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
  “Pharmaceutical sponsor withdrew financial support.” (75% match in meaning)
• Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma
  “Terminated 4/17/07. Drug sponsor withdrew.” (74% match in meaning)
• Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab
  “drug withdrawn from market” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.